Please find attached News Release of our company
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences has announced reaching a 76% enrollment milestone in its global Phase 3 trial for Masupirdine (SUVN-502), an investigational drug for agitation in Alzheimer's Dementia (AAD). The 375-patient, multi-center, randomized, double-blind, placebo-controlled study is being conducted across approximately 80 sites in North America (USA) and Europe. The company expects last patient enrollment by September 2026, with the last patient last visit in January 2027 and top-line data readout by April 2027. Masupirdine is a selective 5-HT6 receptor antagonist designed to offer a non-dopaminergic, non-sedative approach for AAD management.
This is a positive clinical development milestone showing the trial is progressing well. However, it is still a pre-revenue stage pharmaceutical development with no near-term commercial impact. Investors should monitor future trial results expected in Q2/Q3 2027.